Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus
NEW YORK, December 30, 2025, 09:17 ET — Premarket Zenas BioPharma, Inc. shares were flat in premarket trading on Tuesday, with the stock last indicated at $39.05 as of 9:00 a.m. ET. The biotech closed down 8.1% on Monday. Public+1 The pause comes at a sensitive point on the calendar for investors: the company has told investors to expect a late-2025 update from a pivotal trial, a headline that can reset valuations quickly in clinical-stage biotech. In a Nov. 12 press release, founder and Chief Executive Officer Lonnie Moulder said the company expected to deliver “topline results” — the first